torasemide and potassium-sparing agents

C03EB03

Forms & Strengths

Fixed-dose combination products containing torasemide and a potassium-sparing diuretic (e.g., spironolactone or triamterene) vary by regional availability, commonly formulated as torasemide 5 mg / spironolactone 50 mg, torasemide 10 mg / spironolactone 50 mg, or torasemide 5 mg / triamterene 50 mg tablets.

Adult Dosing

Hypertension: Initial dose typically 1 tablet daily (e.g., torasemide 5 mg combined with potassium-sparing agent), adjusted based on blood pressure response.
Edema associated with heart failure or hepatic cirrhosis: Initial dose 1 tablet daily, titrated up to 2-4 tablets daily as needed and tolerated, monitoring electrolytes closely.

Pediatric Dosing

Safety and efficacy in pediatric patients have not been established; use is generally not recommended in children.

Indications

Management of essential hypertension.
Treatment of edema associated with congestive heart failure, hepatic cirrhosis, or renal disease where potassium conservation is clinically desirable.

Mechanism of Action

Torasemide is a loop diuretic that inhibits the Na+/K+/2Cl- cotransporter in the thick ascending limb of the loop of Henle, increasing excretion of water, sodium, chloride, and potassium.
The potassium-sparing agent (e.g., spironolactone or triamterene) acts distally in the nephron to antagonize aldosterone or block epithelial sodium channels, mitigating the hypokalemia induced by torasemide.

Contraindications

Anuria or severe progressive renal failure.
Severe hepatic coma or encephalopathy.
Hyperkalemia or concurrent use of additional potassium-sparing diuretics or potassium supplements.
Hypersensitivity to torasemide, sulfonamide derivatives, or the specific potassium-sparing agent.

Adverse Reactions

Hyperkalemia due to the potassium-sparing component.
Dehydration, hypovolemia, hypotension, and dizziness.
Hyponatremia, hypomagnesemia, and hyperuricemia.
Gastrointestinal disturbances (nausea, diarrhea, cramping).
Endocrine effects (if spironolactone is used, e.g., gynecomastia, menstrual irregularities).

Drug Interactions

ACE inhibitors, ARBs, or direct renin inhibitors: Increased risk of severe hyperkalemia and profound hypotension.
Potassium supplements or other potassium-sparing agents: Contraindicated due to high risk of life-threatening hyperkalemia.
NSAIDs: May attenuate the diuretic and antihypertensive efficacy and increase risk of renal impairment.
Lithium: Decreased renal clearance of lithium, leading to potential lithium toxicity.
Digoxin: Electrolyte disturbances (especially hypomagnesemia or hypokalemia, though mitigated, or secondary shifts) may precipitate digoxin toxicity.

Curated Content: Needs Vetting Before Put to Clinical Use